高级搜索
康艾注射液辅助化疗对晚期非小细胞肺癌患者血清VEGF表达的干预作用[J]. 肿瘤防治研究, 2011, 38(05): 545-547. DOI: 10.3971/j.issn.1000-8578.2011.05.017
引用本文: 康艾注射液辅助化疗对晚期非小细胞肺癌患者血清VEGF表达的干预作用[J]. 肿瘤防治研究, 2011, 38(05): 545-547. DOI: 10.3971/j.issn.1000-8578.2011.05.017
Intervention Effects of Adjuvant Chemotherapy Combined with Kang'ai Injection on Expression of Serum VEGF in Patients with Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(05): 545-547. DOI: 10.3971/j.issn.1000-8578.2011.05.017
Citation: Intervention Effects of Adjuvant Chemotherapy Combined with Kang'ai Injection on Expression of Serum VEGF in Patients with Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(05): 545-547. DOI: 10.3971/j.issn.1000-8578.2011.05.017

康艾注射液辅助化疗对晚期非小细胞肺癌患者血清VEGF表达的干预作用

Intervention Effects of Adjuvant Chemotherapy Combined with Kang'ai Injection on Expression of Serum VEGF in Patients with Advanced Non-small Cell Lung Cancer

  • 摘要: 目的探讨康艾注射液辅助化疗对晚期非小细胞肺癌患者血清VEGF(sVEGF)表达的干预作用。方法将入组的46例晚期非小细胞肺癌患者随机分为实验组(康艾注射液联合化疗组,23例)和对照组(单纯化疗组23例),应用酶联免疫吸附法(ELISA)检测患者治疗前后sVEGF表达水平,并加以比较。结果肺癌患者sVEGF水平明显高于健康对照者(P<0.05)。鳞癌组sVEGF高于腺癌、大细胞癌和腺鳞癌组(P<0.05),而腺癌、大细胞癌和腺鳞癌组之间差异无统计学意义(P>0.05)。中低分化组sVEGF较高分化组有增高但差异无统计学意义(P>0.05)。和治疗前比较,康艾注射液联合化疗组和单纯化疗组治疗后sVEGF水平均明显降低(P<0.05)。和单纯化疗组比较,康艾注射液联合化疗组治疗后sVEGF下降更为显著(P<0.05)。结论康艾注射液辅助化疗可降低晚期非小细胞肺癌患者血清VEGF水平,对抑制肿瘤血管形成有一定的作用。血清VEGF有望作为肿瘤标志物用于肺癌患者的诊断和化疗或生物治疗等的疗效评价。

     

    Abstract: ObjectiveTo explore the effects of adjuvant chemotherapy combined with Kang'ai injection on the expression of serum VEGF in patients with advanced non-small cell lung cancer. MethodsForty-six patients with advanced non-small cell lung cancer were randomly divided equally into two groups .Patients in experimental group were treated with gemcitabine and cisplatin chemotherapy regimen(GP) combined with Kang'ai injection, while patients in the control were just treated with GP regimen chemotherapy. The expression levels of serum vascular endothelial growth factor(sVEGF) were measured by ELISA before and after the treatment,respectively. ResultsThe sVEGF levels of all patients with advanced NSCLC were obviously higher than that of health controls(P<0.05). And the level of sVEGF in squamous cell cancer group was higher than that in adenocarcinoma,large cell carcinoma or adenosquamous carcinoma group,respectively(P<0.05),while there was no significant difference between the latter 3 groups(P>0.05). Compared the well differentiated group,the sVEGF level of moderately and poorly defferentiated group was increased with no significance(P>0.05). The sVEGF level was obviously decreased in two groups after the treatments(P<0.05).Furthermore, the sVEGF level was significantly decreased combination therapy group than that in chemotherapy group(P<0.05). ConclusionKang'ai injection might decrease the expression of serum VEGF in patients with advanced non-small cell lung cancer which suppressed neovascularization. Serum VEGF could be a biomarker for lung cancer diagnosis and therapeutic effect of chemotherapy or biotherapy.

     

/

返回文章
返回